Myrtelle to Present Positive 6-month Post-Treatment Data in Its First- in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference
Wakefield, Mass., Wednesday, May 31, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 31, 2023
This article is featured on another website.
Go to article
March 25, 2026
Biosimilars: Forging a New Path to Accessibility Amid the Reshaping of the Global Biologics Industry
March 25, 2026
Biosimilars: Forging a New Path to Accessibility Amid the Reshaping of the Global Biologics Industry
April 20, 2026
Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026
HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…
April 20, 2026
Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026
HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…